Morning Market Movers

Neurocrine Biosciences

jumped 60.40% to $15.66 after the company reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study. Epizyme

moved up 55.32% to $31.84 after the company reported two major milestone achievements. It announced the achievement of a proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program. Verso Paper

rose 31.70% to $4.23 after the company announced its plans to acquire NewPage for $1.4 billion. Stereotaxis

shares jumped 19.26% to $4.77 after the company Stereotaxis completed the clinical trial of Vdrive with V-Loop.